Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma

International Journal of Oncology

Volumn 33, Issue 5, 2008, Pages 1047-1054

  Paudyal, Bishnuhari ^a   Paudyal, Pramila ^a   Oriuchi, Noboru ^a   Tsushima, Yoshito ^a   Nakajima, Takashi ^a   Endo, Keigo ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

18F fluoro 2 deoxy D glucose; Glucose transporters; Hepatocellular carcinoma; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 5; HEXOKINASE; HEXOKINASE 2; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; GLUCOSE; GLUCOSE TRANSPORTER 2; RADIOPHARMACEUTICAL AGENT; SLC2A2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; WESTERN BLOTTING; CANCER STAGING; KAPLAN MEIER METHOD; LIVER TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SCINTISCANNING; TREATMENT OUTCOME;

AGED; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; GLUCOSE TRANSPORTER TYPE 2; HEXOKINASE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 58149184591     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000093     Document Type: Article

References (29)

1. Bosch FX, Ribes J, Cleries R and Diaz M: Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9: 191-211, 2005.
2. Yu K, Schomisch SJ, Chandramouli V and Lee Z: Hexokinase and glucose-6-phosphatase activity in woodchuck model of hepatitis virus-induced hepatocellular carcinoma. Comp Biochem Physiol C Toxicol Pharmacol 143: 225-231, 2006.
3. 18F-FDG PET. Ann Nucl Med 18: 409-417, 2004.
4. Schelling M, Avril N, Nahrig J, et al: Positron emission tomography using [18F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18: 1689-1699, 2000.
5. Kato H, Miyazaki T, Nakajima M, Fukuchi M, Manda R and Kuwano H: Value of positron emission tomography in the diagnosis of recurrent esophageal carcinoma. Br J Surg 91: 1004-1009, 2004.
6. 18F-FDG PET after radiofrequency ablation therapy. Oncol Rep 18: 1469-1473, 2007.
7. Okazumi S, Isono K, Enomoto K, Kikuchi T, Ozaki M, Yamamoto H, et al: Evaluation of liver tumours using fluorine-18-fluorodeoxyglucose PET: characterization of tumour and assessment of effect of treatment. J Nucl Med 33: 333-339, 1992.
8. Brown RS, Goodman TM, Zasadny KR, Greenson JK and Wahl RL: Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol 29: 443-453, 2002.
9. Gwak GY, Yoon JH, Kim KM, Lee HS, Chung JW and Gores GJ: Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol 42: 358-364, 2005.
10. Godoy A, Ulloa V, Rodriguez F, Reinicke K, Yanez AJ, Garcia Mde L, et al: Differential subcellular distribution of glucose transporters GLUT-1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT-1 and GLUT-5 in breast tumour tissues. J Cell Physiol 207: 614-627, 2006.
11. 18F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma. Ann Nucl Med 22: 83-86, 2008.
12. Younes M, Lechago LV, Somoano JR, Mosharaf M and Lechago J: Wide expression of the human erythrocyte glucose transporter Glut-1 in human cancers. Cancer Res 56: 1164-1167, 1996.
13. Yamamoto T, Seino Y, Fukumoto H, et al: Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 170: 223-230, 1990.
14. 18F-FDG PET. Cancer Sci 99: 260-266, 2008.
15. Brown RS and Wahl RL: Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 72: 2979-2985, 1993.
16. Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, et al: In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 36: 1811-1817, 1995.
17. 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging 31: 1621-1630, 2004.
18. Shiomi S, Nishiguchi S, Ishizu H, Iwata Y, Sasaki N, Tamori A, Habu D, Takeda T, Kubo S and Ochi H: Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 96: 1877-1880, 2001.
19. Seo S, Hatano E, Higashi T, Hara T, Tada M, Tamaki N, Iwaisako K, Ikai I and Uemoto S: Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumour differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 15: 427-433, 2007.
20. Sobin LH and Wittekind C (eds): TNM Classification of Malignant Tumours. 6th edition. Wiley, New York, NY, 2002.
21. 18F]-fluro-2-dexoy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27: 235-238, 1986.
22. Shibata H, Suzuki Y, Omata W, Tanaka S and Kojima I: Dissection of GLUT-4 recycling pathway into exocytosis and endocytosis in rat adipocytes. Evidence that GTP-binding proteins are involved in both processes. J Biol Chem 270: 11489-11495, 1995.
23. Roh MS, Jeong JS, Kim YH, Kim MC and Hong SH: Diagnostic utility of Glut-1 in the differential diagnosis of liver carcinomas. Hepatogastroenterology 51: 1315-1318, 2004.
24. Zimmerman RL, Fogt F, Burke M and Murakata LA: Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma. Oncol Rep 9: 689-692, 2002.
25. Thorens B: Glucose transporters in the regulation of intestinal, renal, and liver glucose fluxes. Am J Physiol 270: 541-553, 1996.
26. Grobholz R, Hacker HJ, Thorens B and Bannasch P: Reduction in the expression of glucose transporter protein GLUT 2 in preneoplastic and neoplastic hepatic lesions and reexpression of GLUT 1 in late stages of hepatocarcinogenesis. Cancer Res 53: 2404-2411, 1993.
27. 18F-FDG uptake. J Nucl Med 46: 1753-1759, 2005.
28. Ito T, Noguchi Y, Satoh S, Hayashi H, Inayama Y and Kitamura H: Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumour stage. Mod Pathol 11: 437-443, 1998.
29. 18F] FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 7: 369-379, 2005.